IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+19.03%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$444M
AUM Growth
+$444M
(-10%)
Cap. Flow
-$53.8M
Cap. Flow
% of AUM
-12.13%
Top 10 Holdings %
Top 10 Hldgs %
35.87%
Holding
93
New
28
Increased
20
Reduced
11
Closed
33
Top Buys
| 1 |
Moderna
MRNA
|
$18M |
| 2 |
Quest Diagnostics
DGX
|
$15.6M |
| 3 |
Cigna
CI
|
$14.9M |
| 4 |
Universal Health Services
UHS
|
$14.1M |
| 5 |
Intuitive Surgical
ISRG
|
$11.7M |
Top Sells
| 1 |
Baxter International
BAX
|
$16.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
$14.4M |
| 3 |
Boston Scientific
BSX
|
$13.6M |
| 4 |
Biogen
BIIB
|
$13.4M |
| 5 |
CVS Health
CVS
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ventyx Biosciences
VTYX
$184M
| $6.89M | 1.45% |
210,000
+110,000
| +110% | +$3.61M |
|
27
Penumbra
PEN
$10.5B
| $6.67M | 1.4% |
+30,000
| New | +$6.67M |
|
28
Cardinal Health
CAH
$36B
| $6.46M | 1.36% |
84,000
-116,000
| -58% | -$8.92M |
|
29
Replimune Group
REPL
$460M
| $5.98M | 1.26% |
220,000
+20,000
| +10% | +$544K |
|
30
Aclaris Therapeutics
ACRS
$223M
| $5.83M | 1.22% |
370,000
+30,000
| +9% | +$473K |
|
31
Viking Therapeutics
VKTX
$3.02B
| $5.64M | 1.18% |
+600,000
| New | +$5.64M |
|
|
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
| $5.27M | 1.11% |
270,000
+75,000
| +38% | +$1.46M |
|
33
Intellia Therapeutics
NTLA
$1.26B
| $5.23M | 1.1% |
150,000
+25,000
| +20% | +$872K |
|
34
Teleflex
TFX
$5.57B
| $4.99M | 1.05% |
+20,000
| New | +$4.99M |
|
35
Cooper Companies
COO
$13.3B
| $4.96M | 1.04% |
+15,000
| New | +$4.96M |
|
|
WBA
36
DELISTED
Walgreens Boots Alliance
WBA
| $4.67M | 0.98% |
+125,000
| New | +$4.67M |
|
|
KDNY
37
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.59M | 0.96% |
+175,000
| New | +$4.59M |
|
|
RVNC
38
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.43M | 0.93% |
240,000
+90,000
| +60% | +$1.66M |
|
39
Doximity
DOCS
$12.6B
| $4.4M | 0.92% |
+131,000
| New | +$4.4M |
|
|
NVRO
40
DELISTED
NEVRO CORP.
NVRO
| $4.32M | 0.91% |
109,000
+9,000
| +9% | +$356K |
|
41
Amicus Therapeutics
FOLD
$2.42B
| $3.99M | 0.84% |
327,000
+197,000
| +152% | +$2.41M |
|
42
Akero Therapeutics
AKRO
$3.65B
| $3.84M | 0.81% |
70,000
-160,000
| -70% | -$8.77M |
|
43
PTC Therapeutics
PTCT
$4.41B
| $3.82M | 0.8% |
100,000
-63,000
| -39% | -$2.4M |
|
44
argenx
ARGX
$44.2B
| $3.79M | 0.8% |
+10,000
| New | +$3.79M |
|
45
Natera
NTRA
$23B
| $3.49M | 0.73% |
+87,000
| New | +$3.49M |
|
46
Envista
NVST
$3.37B
| $3.37M | 0.71% |
100,000
-340,000
| -77% | -$11.4M |
|
|
RETA
47
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.23M | 0.68% |
+85,000
| New | +$3.23M |
|
48
Privia Health
PRVA
$2.84B
| $2.95M | 0.62% |
+130,000
| New | +$2.95M |
|
49
Keros Therapeutics
KROS
$640M
| $2.88M | 0.6% |
+60,000
| New | +$2.88M |
|
50
FibroGen
FGEN
$48.4M
| $2.8M | 0.59% |
+175,000
| New | +$2.8M |
|